China News Service, Beijing, September 27 (Reporter Ruan Yulin) Liu Jingzhen, Chairman of China National Pharmaceutical Group Co., Ltd., said in a speech at the 2021 Sustainable Development Forum in Beijing that Sinopharm Group China Biosciences currently targets the new crown virus beta strain and delta. The research and development of the (Delta) strain inactivated vaccine has been iteratively upgraded. At the same time, the research and development of the mRNA vaccine has broken through the key node, and the first and second clinical research of the recombinant new crown vaccine has been completed.
"Currently, the research and development of inactivated vaccines against the beta strain and the delta strain has been iteratively upgraded. At the same time, our mRNA vaccine research and development has broken through the key nodes, and the first and second clinical studies of the recombinant new crown vaccine have been completed." Liu Jingzhen said, for all the mutations that have been discovered. The second-generation broad-spectrum recombinant vaccine of the strain has completed scientific research. Sinopharm has also reached extensive cooperation with countries in the Middle East, South America, Europe, Africa and other regions, and cooperated with local institutions to carry out Phase III clinical trials to accelerate vaccine research and development.
Liu Jingzhen said that in July this year, with the support of the Epidemic Prevention Innovation Alliance, Sinopharm and International Vaccine Research Institute, Heidelberg University in Germany, Harvard University in the United States, etc., conducted Phase III clinical trials of the Sinopharm’s new crown inactivated vaccine and studied it in designated areas. The protective effect of the new crown inactivated vaccine on variant strains in different populations.
Liu Jingzhen said that in order to achieve accessibility and affordability in developing countries, Sinopharm Group has rapidly expanded its production capacity. By August this year, Sinopharm’s Beijing, Wuhan, Lanzhou, Chengdu, Changchun, and Shanghai R&D and production bases will be the year of the new crown vaccine for the whole system. The production capacity has exceeded 7 billion doses and is capable of meeting international demand.
Sinopharm's China Bio-New Crown Vaccine has been officially registered in 10 countries, and has been approved for use in 107 countries and regions. The vaccinated population covers 196 countries.
(over)